AR065369A1 - Derivados de ciclohexil - amida del acido aril- carboxilico - Google Patents
Derivados de ciclohexil - amida del acido aril- carboxilicoInfo
- Publication number
- AR065369A1 AR065369A1 ARP080100655A ARP080100655A AR065369A1 AR 065369 A1 AR065369 A1 AR 065369A1 AR P080100655 A ARP080100655 A AR P080100655A AR P080100655 A ARP080100655 A AR P080100655A AR 065369 A1 AR065369 A1 AR 065369A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkoxy
- aryl
- amino
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Proceso, composicion farmacéutica y uso para preparar medicamentos para SIDA. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable, éster o pro-fármaco del mismo en donde: X es CH2 o NH; n es 1 o 2; R se seleccionaa partir de cicloalquilo de 3 a 18 átomos de carbono, hetero-cicloalquilo de 3 a 18 átomos de carbono, heteroarilo de 3 a 18 átomos de carbono, arilo de 3 a 18 átomos de carbono; R tiene, opcionalmente fusionado con él, un grupo B seleccionado apartir de cicloalquilo de 3 a 8 átomos de carbono, hetero-cicloalquilo de 3 a 8 átomos de carbono, arilo de 3 a 8 átomos de carbono y heteroarilo de 3 a 8 átomos de carbono; y R y B están cada uno independientemente insustituidos o sustituidos porR1, el cual define uno o más grupos independientemente seleccionados a partir de halogeno, alcoxilo de 1 a 7 átomos de carbono, oxo, alquilo de 1 a 7 átomos de carbono, alcoxilo de 1 a 7 átomos de carbono-alcoxilo de 1 a 7 átomos de carbonoalquenilo de 2 a 7 átomos de carbono, alqueniloxilo de 2 a 7 átomos de carbono, amino, amino-carbonilo, carbamoilo, mono- o di-alquilo de 1 a 7 átomos de carbono-amino, hidroxilo, ciano, mercapto, alcoxilo de 1 a 7 átomos de carbono-carbonilo,arilo, hetero-arilo, carboxilo, sulfanilo, sulfonilo; estando el R1 mismo insustituido o sustituido por uno o más grupos seleccionados a partir de halogeno, hidroxilo, ciano, alquilo de 1 a 6 átomos de carbono, alcoxilo de 1 a 6 átomos de carbono,alquenilo de 2 a 7 átomos de carbono, alqueniloxilo de 2 a 7 átomos de carbono, amino, aminocarbonilo, carbamoilo, mono- o di-alquilo de 1 a 7 átomos de carbono-amino, hidroxilo, ciano, mercapto, alcoxilo de 1 a 7 átomos de carbono-carbonilo, arilo,hetero-arilo, carboxilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07102622 | 2007-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065369A1 true AR065369A1 (es) | 2009-06-03 |
Family
ID=38058317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100655A AR065369A1 (es) | 2007-02-19 | 2008-02-15 | Derivados de ciclohexil - amida del acido aril- carboxilico |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8354431B2 (es) |
| EP (1) | EP2125782B1 (es) |
| JP (1) | JP5180234B2 (es) |
| KR (1) | KR101070984B1 (es) |
| CN (1) | CN101605781B (es) |
| AR (1) | AR065369A1 (es) |
| AT (1) | ATE518854T1 (es) |
| AU (1) | AU2008219317B2 (es) |
| BR (1) | BRPI0807625A2 (es) |
| CA (1) | CA2677565C (es) |
| CL (1) | CL2008000497A1 (es) |
| CR (1) | CR10957A (es) |
| CY (1) | CY1111984T1 (es) |
| DK (1) | DK2125782T3 (es) |
| EA (1) | EA017000B1 (es) |
| EC (1) | ECSP099584A (es) |
| ES (1) | ES2371126T3 (es) |
| GT (1) | GT200900226A (es) |
| HN (1) | HN2009001607A (es) |
| HR (1) | HRP20110793T1 (es) |
| IL (1) | IL200191A (es) |
| MA (1) | MA31206B1 (es) |
| MX (1) | MX2009008145A (es) |
| MY (1) | MY147487A (es) |
| NZ (1) | NZ578663A (es) |
| PE (1) | PE20081785A1 (es) |
| PL (1) | PL2125782T3 (es) |
| PT (1) | PT2125782E (es) |
| RS (1) | RS51986B (es) |
| SI (1) | SI2125782T1 (es) |
| TN (1) | TN2009000345A1 (es) |
| TW (1) | TW200848038A (es) |
| UA (1) | UA97389C2 (es) |
| WO (1) | WO2008101905A1 (es) |
| ZA (1) | ZA200905160B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| MX2023006056A (es) | 2020-11-25 | 2023-06-06 | Akagera Medicines Inc | Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas. |
| KR20250031230A (ko) | 2022-05-25 | 2025-03-06 | 아카제라 메디신즈, 인크. | 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995019436A1 (en) | 1994-01-13 | 1995-07-20 | The Regents Of The University Of California | Mammalian monocyte chemoattractant protein receptors |
| DE69739366D1 (de) | 1996-03-01 | 2009-05-28 | Euroscreen Sa | Aktive und inactive CC-Chemokinrezeptoren und Nukleinsäuremoleküle, die für diesen Rezeptor kodieren |
| AU3375697A (en) * | 1996-05-28 | 1998-01-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cc chemokine receptor 5, antibodies thereto, transgenic animals |
| US6388055B1 (en) | 1996-10-03 | 2002-05-14 | Smithkline Beecham Corporation | Mouse CC-CKR5 receptor polypeptide |
| AR008331A1 (es) | 1997-01-23 | 1999-12-29 | Smithkline Beecham Corp | Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen |
| AU748064B2 (en) * | 1997-12-19 | 2002-05-30 | Takeda Chemical Industries Ltd. | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
| US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| US6235771B1 (en) * | 1998-12-21 | 2001-05-22 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
| WO2001051077A1 (en) | 2000-01-14 | 2001-07-19 | The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services | Methods of regulating il-12 production by administering ccr5 agonists and antagonists |
| WO2002020615A2 (en) | 2000-09-08 | 2002-03-14 | Micromet Ag | Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| EP1434577A1 (en) | 2001-10-03 | 2004-07-07 | Ucb, S.A. | Pyrrolidinone derivatives |
| EP1570860A4 (en) * | 2002-12-13 | 2009-06-03 | Ono Pharmaceutical Co | ANTAGONIST AND AGONIST BINDING TO A STRONG BINDING SITE OF THE CHEMOKINE RECEPTOR |
| JPWO2004098638A1 (ja) * | 2003-05-06 | 2006-07-13 | 小野薬品工業株式会社 | エフェクター細胞機能阻害剤 |
| US7943130B2 (en) * | 2003-12-11 | 2011-05-17 | Yale University | Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation |
| EP1696919B1 (en) * | 2003-12-18 | 2013-10-02 | Incyte Corporation | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| GB0403038D0 (en) * | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
| US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| GEP20084519B (en) | 2004-05-11 | 2008-10-27 | Incyte Corp | 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors |
| GB0412468D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| WO2007062175A2 (en) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Spiro-substituted tricyclic heterocycles cxcr3 antagonists |
| GB0525957D0 (en) | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
| AU2007258907A1 (en) | 2006-06-12 | 2007-12-21 | Pfizer Products Inc. | CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| MX2009003762A (es) | 2006-10-05 | 2009-07-10 | Centocor Ortho Biotech Inc | Antagonistas del receptor cc-quimiocina 2 para el tratamiento de fibrosis. |
| CL2007002958A1 (es) | 2006-10-12 | 2008-05-09 | Epix Delaware Inc | Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr |
| MX2009005252A (es) | 2006-11-17 | 2009-05-28 | Abbott Lab | Aminopirrolidinas como antagonistas del receptor de quimiocina. |
| US20100267765A1 (en) | 2007-02-15 | 2010-10-21 | Stephen John Felstead | Pharmaceutical Compositions and Methods for CCR5 Antagonists |
| WO2008134076A1 (en) | 2007-04-30 | 2008-11-06 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
-
2008
- 2008-02-15 AR ARP080100655A patent/AR065369A1/es not_active Application Discontinuation
- 2008-02-15 PE PE2008000326A patent/PE20081785A1/es not_active Application Discontinuation
- 2008-02-18 PL PL08709083T patent/PL2125782T3/pl unknown
- 2008-02-18 KR KR1020097017079A patent/KR101070984B1/ko not_active Expired - Fee Related
- 2008-02-18 MY MYPI20093281A patent/MY147487A/en unknown
- 2008-02-18 JP JP2009549430A patent/JP5180234B2/ja not_active Expired - Fee Related
- 2008-02-18 CA CA2677565A patent/CA2677565C/en not_active Expired - Fee Related
- 2008-02-18 EP EP08709083A patent/EP2125782B1/en active Active
- 2008-02-18 AT AT08709083T patent/ATE518854T1/de active
- 2008-02-18 US US12/527,469 patent/US8354431B2/en not_active Expired - Fee Related
- 2008-02-18 CN CN200880004192.6A patent/CN101605781B/zh not_active Expired - Fee Related
- 2008-02-18 PT PT08709083T patent/PT2125782E/pt unknown
- 2008-02-18 WO PCT/EP2008/051951 patent/WO2008101905A1/en not_active Ceased
- 2008-02-18 UA UAA200908589A patent/UA97389C2/ru unknown
- 2008-02-18 HR HR20110793T patent/HRP20110793T1/hr unknown
- 2008-02-18 DK DK08709083.3T patent/DK2125782T3/da active
- 2008-02-18 BR BRPI0807625-1A patent/BRPI0807625A2/pt not_active IP Right Cessation
- 2008-02-18 CL CL200800497A patent/CL2008000497A1/es unknown
- 2008-02-18 EA EA200901085A patent/EA017000B1/ru not_active IP Right Cessation
- 2008-02-18 ES ES08709083T patent/ES2371126T3/es active Active
- 2008-02-18 TW TW097105608A patent/TW200848038A/zh unknown
- 2008-02-18 NZ NZ578663A patent/NZ578663A/en not_active IP Right Cessation
- 2008-02-18 RS RS20110474A patent/RS51986B/sr unknown
- 2008-02-18 SI SI200830417T patent/SI2125782T1/sl unknown
- 2008-02-18 MX MX2009008145A patent/MX2009008145A/es active IP Right Grant
- 2008-02-18 AU AU2008219317A patent/AU2008219317B2/en not_active Ceased
-
2009
- 2009-07-23 ZA ZA200905160A patent/ZA200905160B/xx unknown
- 2009-07-24 CR CR10957A patent/CR10957A/es not_active Application Discontinuation
- 2009-07-30 IL IL200191A patent/IL200191A/en not_active IP Right Cessation
- 2009-08-12 GT GT200900226A patent/GT200900226A/es unknown
- 2009-08-17 EC EC2009009584A patent/ECSP099584A/es unknown
- 2009-08-17 TN TNP2009000345A patent/TN2009000345A1/fr unknown
- 2009-08-18 HN HN2009001607A patent/HN2009001607A/es unknown
- 2009-08-31 MA MA32193A patent/MA31206B1/fr unknown
-
2011
- 2011-11-02 CY CY20111101048T patent/CY1111984T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| CU20180011A7 (es) | Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll | |
| PE20190258A1 (es) | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos | |
| AR053306A1 (es) | Derivados de pirazolopiridina. procesos de obtencion y composiciones farmaceuticas. | |
| ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| ES2685568T3 (es) | Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR088441A1 (es) | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales | |
| AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| AR079648A1 (es) | Inhibidores de la replicacion del virus de la hepatitis c | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR067996A1 (es) | Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros. | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| MX2018015236A (es) | Lipido cationico. | |
| RU2015141592A (ru) | АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc | |
| CY1124058T1 (el) | Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| PE20141146A1 (es) | Inhibidores de la enzima activadora de nedd8 | |
| JP2017521436A5 (es) | ||
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR057032A1 (es) | Tigeciclina y metodos de preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |